Russian scientist, professor, and oncologist, Mikhail Blagosklonny, says what doctors have longed looked into may be possible with the drug Rapaymycin. It’s currently used as a prevention to organ rejection, but it’s also one of five drugs now known to prolong the lifespan of mice “We are sitting on something big,” says Blagosklonny.
It has been used for years as an immunosuppressive cocktail that prevents the rejection of transplanted organs, and has extended the lifespan of certain species such as fruit flies, worms and mice. It’s still unclear just how Rapaymycin works to extend life, but scientists worldwide are studying and testing the effects on more animals. In 2014, studies further showed that the drug enhanced the immune systems of humans, and then scientists began to researching how this could slow down the aging process. Read more about Mikhail on Crunchbase.
Rapamycin have been classified as a mTOR inhibitor. Researchers have proven that this drug counteracts aging and age-related diseases in mice and other animals. Oncologist, Mikhail Blagosklonny says this drug can also counteract aging in humans. “Studies must be carried futher so we can know all the ways Rapamycin can help us eliminate diseases.”
MTOR is an enzyme important for survival, growth, how cells behave, and the proliferation of new healthy cells. However, as mTOR slows down, and stops regulating several processes, the body becomes vulnerable to many chronic diseases. But Rapamycin reverses this natural decline in people as they age, and Blagosklonny believes this is one of the most important fountain-of-youth drugs. View Mikhail’s profile on Google Scholar.
Blagosklonny Looks Toward The Future
Last year this time, Research oncologist, Dr. Mikhail Blagosklonny explained his goals for the future. He’s focusing his research on the best methods to eliminate cancer cells while still protecting normal cells. He says Rapaymycin is not only a cost effective method of possibly eliminating cancer, but it could help with other chronic diseases.
Mikhail Blagosklonny earned his M.D. and Ph.D. at Russia’s First Pavlov State Medical University of St. Petersburg. He moved to New York where he was appointed Associate Professor at New York Medical College. In 2002, he became a senior scientist at Albany’s Ordway Research Institute, and in 2009, a research professor at Roswell Park Cancer Institute. Besides serving as a researcher and investigator of how cancer and aging are interrelated, Mikhail Blagosklonny has also been published in journals and serves as editor-in-chief of several publications, including Aging, Cell Cycle, and Oncotarget. He’s active in a variety of professional organizations and current research projects.